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Abstract Toosendanin (TSN), a triterpenoid derivative ex-
tracted from Chinese traditional medicine, has been demon-
strated to be an e¡ective cure for experimental botulism. This
study is designed to explore its antibotulismic mechanism by
Western blotting. The results showed that TSN incubation did
not change the electrophoresis pattern and the amounts of syn-
aptosomal-associated protein of 25 kDa (SNAP-25), syntaxin
and synaptobrevin/vesicle-associated membrane protein in rat
cerebral synaptosomes, but made the synaptosomes completely
resistant to botulinum neurotoxin A (BoNT/A)-mediated cleav-
age of SNAP-25. After binding of BoNT/A to synaptosomes,
TSN still partially antagonized the toxin-mediated cleavage of
SNAP-25. However, TSN-incubated synaptosomal membrane
fraction did not resist the cleavage of SNAP-25 by the light
chain of BoNT/A. It is suggested that the antibotulismic e¡ect
of TSN results from blocking the toxin’s approach to its enzy-
matic substrate.
. 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The botulinum neurotoxins (BoNTs) are the most lethal
biotoxins known to mankind and are responsible for the neu-
roparalytic disease botulism. Seven distinct serotypes of toxin
have been identi¢ed and designated types A^G [1]. It is well
established that the principal target of BoNT is the cholinergic
nerve endings of neuromuscular junctions, where inhibition of
acetylcholine release results in neuromuscular blockade and
paralysis [2]. Each serotype of BoNT consists of a V100
kDa heavy chain (HC) and a V50 kDa light chain (LC),
linked by a single disul¢de bound and non-covalent forces
[3,4]. A four-step mechanism consisting of binding, internal-
ization, translocation and cleaving soluble NSF accessory pro-
tein receptor (SNARE) protein is currently the accepted view
to explain BoNT intoxication [5]. The HC is responsible for
the binding of the toxin to the nerve terminal and for internal-
ization of the LC to the cytosol. The LC is a zinc-dependent
endopeptidase and cleaves one of three SNARE proteins as-
sociated with transmitter release: synaptobrevin/vesicle-asso-
ciated membrane protein (VAMP), synaptosomal-associated
protein of 25 kDa (SNAP-25) and syntaxin. Syntaxin is the
target for BoNT/C, VAMP for BoNT/B, /D, /F and /G, and
SNAP-25 for BoNT/A, /C and /E [6,7].
Although cases of botulism have decreased considerably,
sporadic outbreaks are still reported every year around the
world. Moreover, due to their extreme toxicity and ease of
production, the BoNTs are considered to be formidable threat
agents. Currently, the approved treatment for botulinum in-
toxication is infusion of equine antitoxin. However, the anti-
toxin is only e¡ective in the early stage of BoNT exposure,
and no one can recognize all toxin serotypes and produce
universal neutralization. Since the 1890s, numerous attempts
have been made to develop approved pharmacological treat-
ments for BoNT intoxication, but these e¡orts have met with
little success. For example, Kþ channel blockers, lectins, Hþ-
permeant ionophores, zinc-dependent metalloprotease inhibi-
tors and heavy metal chelators have been tested to evaluate
their antibotulismic e¡ects [8^15]. Some of these compounds
were demonstrated to be e¡ective in reversing the paralytic
actions of BoNT temporarily, but most of them only delayed
the time-to-block or had serious toxic side e¡ects. Clearly, a
safe and reliable drug, especially one that would be e¡ective
after BoNT poisoning, would be desirable.
Toosendanin (C30H38O11, MW=574, TSN) is a plant-de-
rived triterpenoid derivative extracted from the bark of Melia
toosendan Seib et Zucc [16,17]. It has been used in Chinese
traditional medicine as an ascarifuge [18]. In the 1980s, both
in vitro and in vivo experiments revealed that TSN is an
e¡ective antibotulismic agent. For example, TSN can for sev-
eral hours prevent the death of animals (mice, rats and mon-
keys) that have been administered lethal doses of BoNT/A or
/B [19] ; the paralysis time of neuromuscular junction prepa-
rations induced by BoNT/A was lengthened several times after
the preparations were incubated with TSN [20,21]. In partic-
ular, incubation with TSN gave the preparations a high tol-
erance to BoNT. Moreover, a high tolerance to BoNT can be
observed in neuromuscular preparations isolated from rats
which had received a single injection of TSN, and is associ-
ated with the TSN-induced increase in the frequency of mini-
ature end-plate potential over time [22]. Further studies have
shown that TSN inhibited various kinds of Kþ channels, such
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as fast Kþ channels in mouse motor nerve terminals [23],
delayed recti¢er Kþ channels in neuroblastomaUglioma
NG108-15 cells [24], inward recti¢er Kþ channels and large-
and small-conductance Ca2þ-activated Kþ channels in rat hip-
pocampal neurons [25-27]. The inhibition of Kþ currents pro-
vides one of the explanations for TSN-induced initial facili-
tation of transmitter release and antibotulismic e¡ect. The
present study reports our recent ¢nding that TSN treatment
makes synaptosomes resistant to BoNT/A-mediated proteo-
lytic cleavage on their SNAP-25 by the Western blot method.
2. Materials and methods
2.1. Evaluation of curative e¡ect
To con¢rm the therapeutic e¡ect of TSN against animal botulism,
we duplicated the experiments reported by Li et al. [19]. Kunming
mice (male, 18^20 g, supplied by Shanghai Experimental Animal Cen-
ter, Chinese Academy of Sciences) were injected s.c. with BoNT/A
(5 LD50/mouse) and were randomly divided into a BoNT/A-injected
group and a TSN treatment group with 10 mice per group. One hour
later, each mouse in the TSN treatment and BoNT/A-injected groups
was injected i.p. with TSN (8 mg/kg) or solvent (60% propane-1,2-
diol) alone respectively. The survival time of each mouse was recorded
and the survival rate in two groups was counted. All experiments
conformed to the guidelines of the NIH on the ethical use of animals
and all experimental procedures were reviewed and approved by the
Animal Care and Use Committee of Shanghai Institutes for Biological
Sciences. All e¡orts were made to minimize animal su¡ering.
2.2. Synaptosome preparation
Crude synaptosomes were prepared using the procedure described
previously [28]. Brie£y, male Sprague^Dawley rats (provided by
Shanghai Experimental Animal Center, Chinese Academy of Scien-
ces), weighing about 220 g, were killed by cervical dislocation and
decapitation. The cerebral cortices were isolated and the myelin layer
scraped o¡ before homogenization in 0.32 M sucrose (320 mM su-
crose, 5 mM HEPES-NaOH, pH 7.4). The homogenate was spun at
3000Ug for 3 min in a Hitachi CR21G centrifuge and the superna-
tants were spun for 12 min at 14 600Ug. The whiter loosely com-
pacted layer of pellet was resuspended in 0.32 M sucrose and gently
diluted 1:3 into a HEPES-bu¡ered medium (HBM, in mM: NaCl
140, KCl 5, HEPES 20, NaHCO3 5, MgCl2 1, Na2HPO4 1.2, CaCl2
1.3 and glucose 10, pH 7.4). After centrifugation at 11 000Ug for 10 s,
the synaptosomes were pelleted. The pellet was resuspended in HBM
to give a synaptosomal protein concentration of 1.5 mg/ml and stored
at 0‡C until use. The protein concentrations were determined by the
Bradford method [29].
2.3. Synaptosomal membrane preparation
The synaptosomal membrane fraction was isolated as described
previously [30]. Brie£y, synaptosomes resuspended in HBM were di-
luted by adding 9 volumes of distilled water and then homogenized six
times at 2000 rpm. The homogenate was centrifuged at 12 000Ug for
12 min. The pellet, i.e. the synaptosomal membrane fraction, was
resuspended in membrane bu¡er (in mM: HEPES-NaOH 20, NaCl
100, dithiothreitol 10 and 0.05% Triton X-100, pH 7.0) to a required
concentration.
2.4. Sample treatment and Western blot analysis
In the experiments to observe if TSN a¡ects the amounts of
SNARE proteins in synaptosomes (Section 3.2), the isolated synapto-
somes were incubated in HBM with (1U1035 g/ml) or without TSN at
37‡C for 2 h. In other experiments to determine if TSN a¡ects cleav-
age of SNAP-25 by BoNT/A or its LC (Sections 3.3, 3.4 and 3.5), the
samples, synaptosomes or synaptosomal membrane fraction, were in-
cubated in various solutions and with di¡erent protocol (see Figs. 2A^
4A). For control groups, equal solvents were added.
After incubation, the samples were lysed in sodium dodecyl sulfate^
polyacrylamide gel electrophoresis (SDS^PAGE) loading bu¡er (5%
SDS, 5% 2-mercaptoethanol, 50% glycerol, 0.02% bromophenol blue)
and boiled for 5 min. After being vibrated and centrifuged at
12 000Ug for 10 s, the lysates were resolved by 12.5% SDS^PAGE
and electrophoretically transferred to polyvinylidene di£uoride (Phar-
macia) membranes in Tris-glycine transfer bu¡er (25 mM Tris^HCl,
92 mM glycine, 20% methanol, 0.01% SDS). All subsequent experi-
ments were done at room temperature (25‡C). The membranes were
blocked for 1 h with 5% bovine serum albumin in TBST (Tris 2.42 g/l,
NaCl 8 g/l, Tween 20 1 ml/l). The membranes were washed three times
with TBST (3U5 min) and incubated with primary antibody for 1 h.
Following the primary antibody incubation, the membranes were
washed with TBST (3U10 min) and then incubated in a horseradish
peroxidase-conjugated secondary antibody for 1 h. This incubation
step was terminated with three washes (3U10 min) and the immuno-
reactive protein bands were visualized using Western Blotting Lumi-
nol Reagent (Santa Cruz) according to the manufacturer’s instruc-
tions. Membranes were exposed to ¢lm (Kodak X-Omat K Film)
for periods adequate to visualize chemiluminescence bands.
2.5. Materials
TSN used in this work was a sample recrystallized in ethanol with a
purity s 98% [24]. Mouse monoclonal antibodies to SNAP-25, syn-
taxin and synaptobrevin/VAMP were purchased from Synaptic Sys-
tems Company (Germany) and used at dilution ranging between
1:20 000 and 1:200 000. Peroxidase-conjugated goat anti-mouse IgG
(Calbiochem) was used at a dilution of 1:20 000. BoNT/A (V1.8U107
mouse LD50/mg) was a gift from Professor Li P.Z., Chinese Academy
of Military Medicine. BoNT/A was dissolved in phosphate-bu¡ered
saline (52.6 mM NaH2PO4, 26 mM Na2HPO4, 0.2% gelatin, pH 6.5)
and aliquoted and stored at 320‡C. For the synaptosomal membrane
fraction, BoNT/A was treated in 10 mM dithiothreitol at 37‡C for 30
min to separate the HC and LC [31,32]. All other reagents were of
analytical grade.
2.6. Statistical analyses
Di¡erences in protein immunoreactivity between two groups were
determined by scanning densitometry (Scion Image, Scion Corpora-
tion, Frederick, MD, USA). The substrate cleavage data were ex-
pressed as the percentage di¡erence in densitometry between two
groups. All data are expressed as meansTS.E.M. Statistical analysis
was performed using Student’s t-test, and P6 0.05 was considered
signi¢cant.
3. Results and discussion
3.1. Saving botulismic mice from death
In 2^6 h after BoNT/A injection, botulism symptoms ap-
peared in all of the animals. Then the mice in the control
group successively died within 72 h. However, the symptoms
of the animals in the experimental group progressively weak-
ened, and ¢nally disappeared. All mice in the TSN treatment
group returned normal activity in 7 days.
The data obtained from the present and previous studies
performed on intact animals [19] and isolated neuromuscular
preparations [20,22] convince us that TSN is an e¡ective cure
of experimental botulism. TSN has been used as a clinical
ascarifuge in China. It is possible to develop available drug
to a cure for human botulism through studying TSN.
3.2. Having no in£uence on amounts of three SNARE proteins
in synaptosomes
To observe if TSN a¡ects amounts of SNARE proteins,
isolated synaptosomes (0.75 mg protein/ml) were incubated
with TSN (1U1035 g/ml) or without TSN at 37‡C for 2 h,
then were analyzed by SDS^PAGE and immunoblotting (3.75
Wg protein/lane, 12.5% gels) and the contents of syntaxin,
SNAP-25 and VAMP were examined. It was found that there
was no di¡erence in electrophoresis pattern between the con-
trol and the TSN-incubated synaptosomes (Fig. 1A). In par-
ticular, in the TSN-treated synaptosomes, neither lost electro-
phoresis bands nor new ones could be observed. The amounts
of syntaxin, SNAP-25 and VAMP in the TSN-incubated syn-
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aptosomes were 102.5 T 4.9% (n=8), 102.2 T 10.1% (n=10)
and 101.2T 7.3% (n=6) of their controls, respectively (Fig.
1B,C). The results showed that TSN did not change the elec-
trophoresis pattern of proteins and amounts of the three
SNARE proteins in synaptosomes (Ps 0.05 vs. control), im-
plying that TSN had no direct e¡ects on SNARE proteins.
3.3. Eliminating proteolytic cleavage of SNAP-25 by BoNT/A
in synaptosomes
As SNAP-25 is the proteolytic substrate of BoNT/A, a con-
tent decrease of SNAP-25 in synaptosomes incubated with
BoNT/A can be detected by Western blotting. In our exper-
imental condition, the amount of SNAP-25 decreased to
78.6T 6.1% of control after incubation with BoNT/A (0.4
mg/ml) (n=6, P6 0.001, Fig. 2B,C). However, preincubation
with TSN made the synaptosomes resistant to the proteolytic
cleavage of SNAP-25 mediated by BoNT/A. The amount of
SNAP-25 in the synaptosomes which were preincubated with
TSN (1U1035 g/ml) for 20 min before the incubation with
BoNT/A was 98.0T 8.0% of the control (n=6, Ps 0.05 vs.
control), indicating that TSN completely eliminated the action
of BoNT/A to cleave its substrate. Decreasing the concentra-
tion of TSN to 5U1037 g/ml, the antagonizing e¡ect of TSN
on the BoNT/A-induced cleavage of SNAP-25 was still ob-
served (data not shown).
Previous studies performed on isolated neuromuscular junc-
tion preparations demonstrated that the antibotulismic site of
TSN was at a neurotransmitter release process of synaptic
transmission on which both TSN and BoNT, two presynaptic
blockers, acted pharmacologically [20,22]. The present inves-
tigation further demonstrated that the antibotulismic e¡ect of
TSN resulted from its interfering with the cleavage of SNAP-
25 by BoNT/A. After incubation with TSN, the synaptosomes
resisted BoNT/A-mediated cleavage on their SNAP-25.
3.4. Having no direct e¡ect on endopeptidase activity of
BoNT/A light chain
To determine if the observation in Section 3.3, namely the
Fig. 1. TSN had no in£uence on the amounts of SNARE proteins in rat cerebral synaptosomes. Synaptosomes were incubated with (1U1035
g/ml) or without TSN solution for 2 h at 37‡C, and samples were analyzed by SDS^PAGE and immunoblotting (3.75 Wg protein/lane, 12.5%
gels). Neither the electrophoresis pattern (A) nor the amount of syntaxin, SNAP-25 or synaptobrevin/VAMP (B,C) of the TSN-treated group
was di¡erent from that of the control (Ps 0.05). Data expressed in C are from 6^10 experiments.
Fig. 2. TSN antagonized BoNT/A-induced cleavage of SNAP-25 in
rat cerebral synaptosomes. After incubation in normal, BoNT/A
(0.4 mg/ml)- or TSN (1U1035 g/ml)-containing HBM (A), the syn-
aptosomes were analyzed by SDS^PAGE and immunoblotting (3.75
Wg protein/lane, 12.5% gels). TSN treatment made synaptosomes re-
sistant to SNAP-25 cleavage induced by BoNT/A (B,C). Data ex-
pressed in C are from 6 experiments, ***P6 0.001 vs. control,
##P6 0.01 vs. BoNT group, Ps 0.05 between BoNT/A+TSN group
and control.
FEBS 27873 20-11-03
J.-Y. Zhou et al./FEBS Letters 555 (2003) 375^379 377
elimination of BoNT/A cleavage on SNAP-25 after TSN
treatment, results from a direct inhibition of endopeptidase
activity of LC of BoNT/A by TSN, similar experiments
were performed but using synaptosomal membrane fractions
instead of synaptosomes and reduced BoNT/A instead of in-
tact BoNT/A (Fig. 3). In this case, in spite of preincubating
the samples with or without TSN, SNAP-25 was cleaved sim-
ilarly by the LC of BoNT/A. The amounts of remaining
SNAP-25 were 72.2T 3.2% (n=4) and 70.9T 6.9% (n=4) of
control respectively, indicating that TSN did not have a direct
action on the endopeptidase activity of the LC of BoNT/A.
The action of TSN is to interfere with the enzyme^substrate
approach in a certain way.
3.5. Partially antagonizing BoNT/A cleavage of SNAP-25 in
synaptosomes after binding of the toxin
The binding, as the ¢rst step of BoNT action, has been
demonstrated to be temperature-independent and can be ¢n-
ished at 0‡C [33]. Previous study showed that the binding of
BoNT to synaptosomes could be equilibrated in 10 min at 0‡C
[34]. So, the step can be separated from subsequent temper-
ature- and energy-dependent steps by controlling the incuba-
tion temperature.
In these experiments, synaptosomes were ¢rst incubated
with BoNT/A (0.4 mg/ml)-containing solution at 0‡C for 10
min, then at 37‡C for 2 h after addition of TSN (1U1035 g/
ml) or corresponding bu¡er to the solution (Fig. 4A). The
results showed that the amounts of SNAP-25 determined by
Western blot in the BoNT/A intoxication group and TSN
treatment group were 81.9T 5.4% and 92.0T 8.7% of control
(n=10) respectively. There was a signi¢cant di¡erence be-
tween them (P6 0.05). The results indicate that TSN can still
antagonize BoNT/A action to cleave SNAP-25 after binding
of the toxin. Based on the fact that the amount of SNAP-25 in
the TSN-treated group was signi¢cantly lower than that in the
control group (P6 0.05), the antagonizing e¡ect of TSN, after
binding of BoNT/A, is only partial. The results also imply
that an e¡ect of TSN on binding of the toxin could not be
excluded.
In conclusion, the obtained data show that the protective
e¡ect of TSN against BoNT/A-induced cleavage of SNAP-25
does not result from its direct inhibition of the endopeptidase
activity of the toxin, but from its interference with the LC of
the toxin^substrate approach in a certain way.
Fig. 3. TSN had no e¡ect on dithiothreitol-treated BoNT/A-induced
cleavage of SNAP-25 in rat cerebral synaptosomal membrane frac-
tions. BoNT/A was reduced by 10 mM dithiothreitol at 37‡C for
30 min to separate its heavy and light chains. After incubating the
synaptosomal membrane fraction with reduced BoNT/A in dif-
ferent conditions (A), the samples were analyzed by SDS^PAGE
and immunoblotting (3.75 Wg protein/lane, 12.5% gels). TSN treat-
ment did not a¡ect cleavage of SNAP-25 in the membrane fraction
by the reduced toxin (B,C). Data expressed in C are from four
experiments. **P6 0.01 vs. control, but Ps 0.05 between BoNT
and BoNT+TSN groups.
Fig. 4. TSN partially antagonized BoNT/A cleavage of SNAP-25 in
rat cerebral synaptosomes after binding of the toxin. Synaptosomes
were ¢rst incubated with BoNT/A at 0‡C for 10 min, then incuba-
ted for 2 h at 37‡C after adding TSN (A). The samples were ana-
lyzed by SDS^PAGE and immunoblotting (3.75 Wg protein/lane,
12.5% gels). TSN made the synaptosomes partially resistant to the
cleavage of SNAP-25 (B). Data expressed in B are from 10 experi-
ments. ***P6 0.001 vs. control, *P6 0.05 vs. BoNT group or vs.
control.
FEBS 27873 20-11-03
J.-Y. Zhou et al./FEBS Letters 555 (2003) 375^379378
Acknowledgements: This work was supported by the National Basic
Research Program of China (G1999054000), the National Natural
Science Foundation of China (30170302) and the Basic Research Pro-
gram of Shanghai (02JC14011). The authors acknowledge the help
provided by Miss W.P. Wang in experiments.
References
[1] Simpson, L.L. (1986) Annu. Rev. Pharmacol. Toxicol. 26, 427^
453.
[2] Burgen, A.S.V., Dickend, F. and Zatman, L.J. (1949) J. Physiol.
109, 10^24.
[3] Lacy, D.B., Tepp, W., Cohen, A.C., DasGupta, B.R. and Ste-
vens, R.C. (1998) Nat. Struct. Biol. 5, 898^902.
[4] Swaminathan, S. and Eswaramoorthy, S. (2000) Nat. Struct.
Biol. 7, 693^699.
[5] Montecucco, C., Papini, E. and Schiavo, G. (1994) FEBS Lett.
346, 92^98.
[6] Schiavo, G., Matteoli, M. and Montecucco, C. (2000) Physiol.
Rev. 80, 717^766.
[7] Humeau, Y., Doussau, F., Grant, N.J. and Poulain, B. (2000)
Biochimie 82, 427^446.
[8] Adler, M., Scovill, J., Parker, G., Lebeda, F.J., Piotrowski, J.
and Deshpande, S.S. (1995) Toxicon 33, 527^537.
[9] Adler, M., Macdonald, D.A., Sellin, L.C. and Parker, G.W.
(1996) Toxicon 34, 237^249.
[10] Adler, M., Dinterman, R.E. and Wannemacher, R.W. (1997)
Toxicon 35, 1089^1100.
[11] Adler, M., Nicholson, J.D. and Hackley, B.E. (1998) FEBS Lett.
429, 234^238.
[12] Bakry, N., Kamata, Y. and Simpson, L.L. (1991) J. Pharmacol.
Exp. Ther. 258, 830^836.
[13] Kalandakanond, S. and Co⁄eld, J.A. (2001) J. Pharmacol. Exp.
Ther. 296, 980^986.
[14] Sheridan, R.E. (1996) Toxicon 34, 849^855.
[15] Deshpande, S.S., Sheridan, R.E. and Adler, M. (1995) Toxicon
33, 551^557.
[16] Chang, C.C., Hsie, T.H., Chen, S.F. and Liang, H.T. (1975) Acta
Chim. Sin. 33, 35^47.
[17] Shu, G.X. and Liang, X.T. (1980) Acta Chim. Sin. 38, 196^198.
[18] Wang, Y.B. and Wen, Y.X. (1959) J. Tradit. Chin. Med. 262, 46^
49.
[19] Li, P.Z., Zhou, J., Miao, W.Y., Ding, F.H., Meng, J.Y., Jia,
G.R., Li, J.F., Ye, H.J., He, X.Y., Chen, M.Y. and Huang,
Z.M. (1982) Chin. Tradit. Herb. Drugs 13, 28^30.
[20] Shi, Y.L. and Xu, K. (1983) Chin. Sci. Bull. 28, 885^887.
[21] Li, P.Z. and Sun, G.Z. (1983) Acta Physiol. Sin. 35, 480^483.
[22] Shi, Y.L. and Hsu, K. (1983) Jpn. J. Physiol. 33, 677^680.
[23] Xu, Y.F. and Shi, Y.L. (1993) Brain Res. 631, 46^50.
[24] Hu, Q., Huang, F.S. and Shi, Y.L. (1997) Brain Res. 751, 47^53.
[25] Wang, Z.F. and Shi, Y.L. (2001) Neuroscience 104, 41^47.
[26] Wang, Z.F. and Shi, Y.L. (2001) Neurosci. Lett. 303, 13^16.
[27] Wang, Z.F. and Shi, Y.L. (2001) Neurosci. Res. 40, 211^215.
[28] McMahon Foran, P., Dolly, J.O., Verhage, M., Wiegant, V.M.
and Nicholls, D.G. (1992) J. Biol. Chem. 267, 21338^21343.
[29] Bradford, M.M. (1976) Anal. Biochem. 72, 248^254.
[30] von Mollard, G.F., Su«dhof, T.C. and Jahn, R. (1991) Nature
349, 79^81.
[31] Schiavo, G., Shone, C.C., Bennett, M.K., Scheller, R.H. and
Montecucco, C. (1995) J. Biol. Chem. 270, 10566^10570.
[32] Yamasaki, S., Hu, Y., Binz, T., Kalkuhl, A., Tamura, T., Jahn,
R., Kandel, E. and Niemann, H. (1994) Proc. Natl. Acad. Sci.
USA 91, 4688^4692.
[33] Dolly, J.O., Black, J., Williams, R.S. and Melling, J. (1984) Na-
ture 307, 457^460.
[34] Agui, T., Syuto, B., Oguma, K., Iida, H. and Kubo, S. (1983)
J. Biochem. (Tokyo) 94, 521^527.
FEBS 27873 20-11-03
J.-Y. Zhou et al./FEBS Letters 555 (2003) 375^379 379
